What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide and a selective agonist of the growth hormone secretagogue receptor (GHS-R), also known as the ghrelin receptor. It has the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂, a molecular formula of C₃₈H₄₉N₉O₅, a molecular weight of 711.9 g/mol, and CAS Number 170851-70-4. It is supplied as a lyophilised reference peptide for laboratory research use only.

The amide-capped C-terminus and two D-amino acids distinguish Ipamorelin from earlier growth hormone secretagogue peptides and are characteristic features of its molecular identity. It is supplied as a research reference material within the GH-axis research category and is not a medicine, dietary supplement, or veterinary product.

Is Ipamorelin legal in the UK?

Ipamorelin is not a controlled drug under the Misuse of Drugs Act 1971 and is not a scheduled substance in the UK. It is supplied strictly as a laboratory research chemical and is not licensed as a medicinal product. It has no UK marketing authorisation and must not be sold, supplied, or promoted for human or veterinary consumption.

Purchasers are responsible for ensuring compliance with all applicable laws and regulations within their own jurisdiction. Please refer to our Research Use Only disclaimer for further information.

How is identity and quality verified?

Each production batch undergoes independent analytical testing before release. Purity is determined by high-performance liquid chromatography (HPLC) and is typically 99% or greater, while molecular identity is confirmed by mass spectrometry against the expected molecular mass for C₃₈H₄₉N₉O₅ (CAS 170851-70-4; PubChem CID 9831659).

Every batch is accompanied by a batch-specific Certificate of Analysis (CoA) detailing the analytical results. This level of verification distinguishes a characterised research reference material from unverified products.

What does research investigate?

Published scientific literature investigates Ipamorelin as a research tool for studying GHS-R signalling and the ghrelin/growth hormone secretagogue pathway in laboratory and pre-clinical models.

Searches for terms such as Ipamorelin benefits, effects, or results should not be interpreted as evidence of therapeutic benefit in humans. Current research does not establish safety or efficacy for human use. Ipamorelin is not a licensed medicine, and no human or veterinary application is intended or implied.

How does Ipamorelin compare with CJC-1295 and Sermorelin?

Although frequently discussed together in the scientific literature, these are distinct research molecules within the growth hormone axis.

• Ipamorelin is a selective GHS-R (ghrelin receptor) agonist.
• CJC-1295 (No DAC) and CJC-1295 (DAC) are synthetic growth hormone-releasing hormone (GHRH) analogues.
• Sermorelin is also a GHRH analogue.

The common search phrase "CJC-1295 and Ipamorelin" reflects scientific interest in studying two separate receptor pathways within laboratory models. This comparison relates solely to receptor pharmacology and research design and should not be interpreted as guidance for use in humans.

Storage and Supply

Ipamorelin is supplied as a white to off-white lyophilised powder for laboratory research. For research purposes, the material may be reconstituted using an appropriate laboratory-grade solvent such as bacteriostatic water.

Store the lyophilised material at −20°C, protected from moisture and light. Following reconstitution, store between 2–8°C and handle in accordance with established laboratory procedures.

Supplied per vial as a laboratory research reference material and dispatched from the UK.

For Research Use Only. Not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease.